Oral Anticoagulation: Would You Recognize a Candidate?

News
Poll

What does the patient with atrial fibrillation who would benefit from oral anticoagulation look like today? Q & A, here.

The “face” of the patient with atrial fibrillation (AF) who will benefit from some level of anticoagulation therapy is changing. The most recent change in look is a result of updated guidelines put forth by the American Heart Association, American College of Cardiology, and Heart Rhythm Society in 2014.

Which of the following are current guideline recommendations for oral anticoagulation in patients with atrial fibrillation?

A. Use oral anticoagulation in male patients with CHA2DS2-VASc score ≥1 and female patients with a score ≥2.
B. Use oral anticoagulation in CHA2DS2-VASc stroke risk score ≥2 for patients of both sexes.
C. Use oral anticoagulation in CHA2DS2 stroke risk score ≥2 for patients of both sexes.
D. All of the above
Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds / Image credit: ©9nong/AdobeStock

Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds

Sydney Jennings
January 31st 2025
Article

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

CVD Remains Leading Cause of Death in US: AHA 2025 Statistical Update / Image credit: ©Rasi/AdobeStock

CVD Remains Leading Cause of Death in US: AHA 2025 Statistical Update

Sydney Jennings
January 27th 2025
Article

Cardiovascular disease is still the leading cause of death in the US, driven by rising rates of obesity, diabetes, and hypertension, according to new report.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Patient Care Staff
January 17th 2025
Article

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

FDA Limit Nicotine Content in Cigarettes, Cigars, Other Products / image credit ©Solid Photos/stock.adobe.com

FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products

Richard Payerchin
January 16th 2025
Article

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

© 2025 MJH Life Sciences

All rights reserved.